CM Management’s Royalty Pharma RPRX Stock Holding History

CM Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.01M	Hold	125,000	–	–	4.45%	3
2026 Q1	$6M	Buy	125,000 +50,000	+67%	+$2.19M	5.01%	3
2025 Q4	$2.9M	Buy	75,000 +25,000	+50%	+$953K	2.44%	11
2025 Q3	$1.76M	Buy	+50,000	New	+$1.81M	1.47%	23
2025 Q1	–	Sell	-160,000	Closed	-$4.08M	–	61
2024 Q4	$4.08M	Hold	160,000	–	–	3.65%	6
2024 Q3	$4.53M	Hold	160,000	–	–	3.61%	7
2024 Q2	$4.22M	Hold	160,000	–	–	3.87%	5
2024 Q1	$4.86M	Buy	160,000 +35,000	+28%	+$1.03M	4.08%	4
2023 Q4	$3.51M	Buy	+125,000	New	+$3.44M	2.82%	7

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CM Management's RPRX Position: Q2 2026 in Review

CM Management held its Royalty Pharma (RPRX) position steady in Q2 2026 at 125,000 shares worth $7.01M. The position accounts for 4.45% of the portfolio, ranked #3.

CM Management first reported a position in RPRX in Q4 2023 and has held it in 9 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

CM Management held 125,000 shares of Royalty Pharma worth $7.01M as of Q2 2026.
CM Management left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 4.45% of CM Management's portfolio in Q2 2026, its #3 holding.
CM Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 9 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.